Tengjun Biotechnology (CHGH) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CHGH Annual Balance Sheets →
Reviewing balance sheet figures over time helps illustrate how Tengjun Biotechnology manages its resources, obligations, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2023)
(Mar 31 2023) (Dec 31 2022) (Sep 30 2022) (Jun 30 2022)
Assets
Cash & cash equivalent25.11
Cash & Short-term Investments25.00
Other Receivables, Net, Current400.03
Inventories2.35
Other Current Assets3.01
Total Current Assets430.50
Equipment/Property/Plant Net0.62
Other Assets, Noncurrent0.00
Advance To Supplier0.07
Due From Related Party Current2.94
Construction In Progress7.85
Total Assets438.96
Liabilities
Accounts Payable and Accrued Liabilities, Current LI5.72
Accrued Liabilities, Current0.00
Other Liabilities, Current32.54
Taxes Payable0.00
Customer Advances, Current385.44
Total Current Liabilities423.70
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Related Party Loans7.34
Total Liabilities423.70
Stockholders' Equity
Common Stock Value0.10
Additional Paid In Capital Common Stock8.99
Retained Earnings / Accumulated Deficit8.07
Other Equity-2.30
Common Stockholder's Equity14.86
Non-controlling interests & other0.41
Total Stockholder's Equity15.26
Liabilities & Stockholder's Equity438.96
4 historic quarters locked

Sign in to unlock the full Tengjun Biotechnology balance sheet history.

About Tengjun Biotechnology Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001213900-23-067340

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.